ABGX starts another ABX-EGF Phase II

Abgenix (ABGX) and partner Immunex (IMNX) began an open-label Phase II trial of ABX-EGF as a monotherapy in up to 100 metastatic colorectal cancer patients who have failed chemotherapy. ABX-EGF, a mon...